Does Vitamin D Reduce Risk of Developing Type II DM in High Risk Individuals
NCT ID: NCT01170468
Last Updated: 2018-03-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
25 participants
INTERVENTIONAL
2011-12-31
2014-01-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators plan to conduct a 2 year, double blind, randomized, placebo controlled trial on the effect of vitamin D3 supplement on the incidence of type II DM in high risk individuals.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Does Vitamin D Improve Glycemic Control in Type II DM?
NCT01170442
Vitamin D and Type 2 Diabetes Study
NCT01942694
Is Vitamin D2 Treatment-associated Decrease in 25(OH)D3 Level a Reciprocal Phenomena?
NCT03035084
Vitamin D in Minorities With Prediabetes
NCT00876928
African American Children, Glycemic Control, and Type 2 Diabetes
NCT01325987
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vitamin D3
Vitamin D3 5000 IU daily
Vitamin D3
Vitamin D3 5000 IU orally, daily for 2 years
Placebo
Placebo daily
Placebo
Placebo orally, daily for 2 years
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vitamin D3
Vitamin D3 5000 IU orally, daily for 2 years
Placebo
Placebo orally, daily for 2 years
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Who consume no more than one serving of milk/day
* Do not take vitamin supplement
* Habitually have less than 10 hour of sun exposure per week
* Don't suffer from granulomatus conditions, liver disease, kidney disease, or diabetes
* Don't take anticonvulsants, barbiturates, steroids, or antidiabetic medications.
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
King Faisal Specialist Hospital & Research Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Muhammad Maher Hammami
Chairman, Department of Clinical Studies & Empirical Ethics
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Muhammad M Hammami, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
King Faisal Specialist Hospital & Research Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
King Faisal Specialist Hospital & Research Center
Riyadh, , Saudi Arabia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RAC 2101040
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.